Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 61 to 68 of 68 entries
Sorted by: Best Match Show Resources per page
Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE).

Journal of the Endocrine Society

de Tersant M, Généré L, Freyçon C, Villebasse S, Abbas R, Barlier A, Bodet D, Corradini N, Defachelles AS, Entz-Werle N, Fouquet C, Galmiche L, Gandemer V, Lacour B, Mansuy L, Orbach D, Pluchart C, Réguerre Y, Rigaud C, Sarnacki S, Sirvent N, Stephan JL, Thebaud E, Gimenez-Roqueplo AP, Brugières L.
PMID: 32432211
J Endocr Soc. 2020 Apr 03;4(5):bvaa039. doi: 10.1210/jendso/bvaa039. eCollection 2020 May 01.

PURPOSE: The purpose of this work is to assess the clinical outcome of pediatric patients diagnosed with pheochromocytoma and paraganglioma (PPGL) detected in France since 2000.METHODS: A retrospective multicenter study was conducted that included all patients younger than 18...

Cite
de Tersant M, Généré L, Freyçon C, et al. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). J Endocr Soc. 2020;4(5):bvaa039doi: 10.1210/jendso/bvaa039.
de Tersant, M., Généré, L., Freyçon, C., Villebasse, S., Abbas, R., Barlier, A., Bodet, D., Corradini, N., Defachelles, A. S., Entz-Werle, N., Fouquet, C., Galmiche, L., Gandemer, V., Lacour, B., Mansuy, L., Orbach, D., Pluchart, C., Réguerre, Y., Rigaud, C., Sarnacki, S., Sirvent, N., Stephan, J. L., Thebaud, E., Gimenez-Roqueplo, A. P., & Brugières, L. (2020). Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). Journal of the Endocrine Society, 4(5), bvaa039. https://doi.org/10.1210/jendso/bvaa039
de Tersant, Marie, et al. "Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE)." Journal of the Endocrine Society vol. 4,5 (2020): bvaa039. doi: https://doi.org/10.1210/jendso/bvaa039
de Tersant M, Généré L, Freyçon C, Villebasse S, Abbas R, Barlier A, Bodet D, Corradini N, Defachelles AS, Entz-Werle N, Fouquet C, Galmiche L, Gandemer V, Lacour B, Mansuy L, Orbach D, Pluchart C, Réguerre Y, Rigaud C, Sarnacki S, Sirvent N, Stephan JL, Thebaud E, Gimenez-Roqueplo AP, Brugières L. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). J Endocr Soc. 2020 Apr 03;4(5):bvaa039. doi: 10.1210/jendso/bvaa039. eCollection 2020 May 01. PMID: 32432211; PMCID: PMC7217277.
Copy Download .nbib Format: NLM
Association between genetic polymorphisms and platinum-induced ototoxicity in children.

Oncotarget

Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, Chastagner P, Corradini N, Entz-Werle N, Vérité C, Landmanparker J, Sudour-Bonnange H, Pasquet M, Verschuur A, Faure-Conter C, Doz F, Tréluyer JM.
PMID: 30112115
Oncotarget. 2018 Jul 20;9(56):30883-30893. doi: 10.18632/oncotarget.25767. eCollection 2018 Jul 20.

Platinum is extensively used in the treatment of several childhood cancers. However, ototoxicity is one of the most notable adverse effects, especially in children. Several studies suggest that genetics may predict its occurrence. Here, polymorphisms associated with platinum-induced ototoxicity...

Cite
Lui G, Bouazza N, Denoyelle F, et al. Association between genetic polymorphisms and platinum-induced ototoxicity in children. Oncotarget. 2018;9(56):30883-30893doi: 10.18632/oncotarget.25767.
Lui, G., Bouazza, N., Denoyelle, F., Moine, M., Brugières, L., Chastagner, P., Corradini, N., Entz-Werle, N., Vérité, C., Landmanparker, J., Sudour-Bonnange, H., Pasquet, M., Verschuur, A., Faure-Conter, C., Doz, F., & Tréluyer, J. M. (2018). Association between genetic polymorphisms and platinum-induced ototoxicity in children. Oncotarget, 9(56), 30883-30893. https://doi.org/10.18632/oncotarget.25767
Lui, Gabrielle, et al. "Association between genetic polymorphisms and platinum-induced ototoxicity in children." Oncotarget vol. 9,56 (2018): 30883-30893. doi: https://doi.org/10.18632/oncotarget.25767
Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, Chastagner P, Corradini N, Entz-Werle N, Vérité C, Landmanparker J, Sudour-Bonnange H, Pasquet M, Verschuur A, Faure-Conter C, Doz F, Tréluyer JM. Association between genetic polymorphisms and platinum-induced ototoxicity in children. Oncotarget. 2018 Jul 20;9(56):30883-30893. doi: 10.18632/oncotarget.25767. eCollection 2018 Jul 20. PMID: 30112115; PMCID: PMC6089394.
Copy Download .nbib Format: NLM
Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.

PloS one

Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C.
PMID: 34941934
PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021.

BACKGROUND: Chronic Lung Allograft Dysfunction (CLAD) is a major obstacle for long term survival after lung transplantation (LTx). Besides Bronchiolitis Obliterans Syndrome, two other phenotypes of CLAD, restrictive allograft syndrome (RAS) and mixed phenotype, have been described. Trials to...

Cite
Gottlieb J, Verleden GM, Perchl M, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021;16(12):e0260881doi: 10.1371/journal.pone.0260881.
Gottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallee, A., Brugière, O., & Bravo, C. (2021). Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PloS one, 16(12), e0260881. https://doi.org/10.1371/journal.pone.0260881
Gottlieb, Jens, et al. "Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial." PloS one vol. 16,12 (2021): e0260881. doi: https://doi.org/10.1371/journal.pone.0260881
Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021. PMID: 34941934; PMCID: PMC8700042.
Copy Download .nbib Format: NLM
Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection.

Frontiers in human neuroscience

Senova S, Lefaucheur JP, Brugières P, Ayache SS, Tazi S, Bapst B, Abhay K, Langeron O, Edakawa K, Palfi S, Bardel B.
PMID: 33716700
Front Hum Neurosci. 2021 Feb 25;15:646268. doi: 10.3389/fnhum.2021.646268. eCollection 2021.

No abstract available.

Cite
Senova S, Lefaucheur JP, Brugières P, et al. Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Front Hum Neurosci. 2021;15:646268doi: 10.3389/fnhum.2021.646268.
Senova, S., Lefaucheur, J. P., Brugières, P., Ayache, S. S., Tazi, S., Bapst, B., Abhay, K., Langeron, O., Edakawa, K., Palfi, S., & Bardel, B. (2021). Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Frontiers in human neuroscience, 15646268. https://doi.org/10.3389/fnhum.2021.646268
Senova, Suhan, et al. "Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection." Frontiers in human neuroscience vol. 15 (2021): 646268. doi: https://doi.org/10.3389/fnhum.2021.646268
Senova S, Lefaucheur JP, Brugières P, Ayache SS, Tazi S, Bapst B, Abhay K, Langeron O, Edakawa K, Palfi S, Bardel B. Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Front Hum Neurosci. 2021 Feb 25;15:646268. doi: 10.3389/fnhum.2021.646268. eCollection 2021. PMID: 33716700; PMCID: PMC7947337.
Copy Download .nbib Format: NLM
ALK inhibitors for ALK-altered paediatric malignancies.

The Lancet. Oncology

Brugieres L, Afify Z, Lowe E.
PMID: 34780708
Lancet Oncol. 2021 Dec;22(12):1646-1648. doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12.

No abstract available.

Cite
Brugieres L, Afify Z, Lowe E. ALK inhibitors for ALK-altered paediatric malignancies. Lancet Oncol. 2021;22(12):1646-1648doi: 10.1016/S1470-2045(21)00608-2.
Brugieres, L., Afify, Z., & Lowe, E. (2021). ALK inhibitors for ALK-altered paediatric malignancies. The Lancet. Oncology, 22(12), 1646-1648. https://doi.org/10.1016/S1470-2045(21)00608-2
Brugieres, Laurence, et al. "ALK inhibitors for ALK-altered paediatric malignancies." The Lancet. Oncology vol. 22,12 (2021): 1646-1648. doi: https://doi.org/10.1016/S1470-2045(21)00608-2
Brugieres L, Afify Z, Lowe E. ALK inhibitors for ALK-altered paediatric malignancies. Lancet Oncol. 2021 Dec;22(12):1646-1648. doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12. PMID: 34780708.
Copy Download .nbib Format: NLM
A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome.

The European respiratory journal

Parquin F, Zuber B, Vallée A, Taupin JL, Cuquemelle E, Malard S, Neuville M, Devaquet J, Le Guen M, Fessler J, Beaumont L, Picard C, Hamid A, Colin de Verdière S, Grenet D, De Miranda S, Glorion M, Sage E, Pricopi C, De Wolf J, Brun AL, Longchampt E, Cerf C, Roux A, Brugière O.
PMID: 34016620
Eur Respir J. 2021 Nov 18;58(5). doi: 10.1183/13993003.04090-2020. Print 2021 Nov.

BACKGROUND: Pre-formed donor-specific antibodies (DSAs) are associated with worse outcome after lung transplantation (LTx) and might limit access to LTx. A virtual crossmatch-based strategy for perioperative desensitisation protocol has been used for immunised LTx candidates since 2012 at Foch...

Cite
Parquin F, Zuber B, Vallée A, et al. A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. Eur Respir J. 2021;58(5)doi: 10.1183/13993003.04090-2020.
Parquin, F., Zuber, B., Vallée, A., Taupin, J. L., Cuquemelle, E., Malard, S., Neuville, M., Devaquet, J., Le Guen, M., Fessler, J., Beaumont, L., Picard, C., Hamid, A., Colin de Verdière, S., Grenet, D., De Miranda, S., Glorion, M., Sage, E., Pricopi, C., De Wolf, J., Brun, A. L., Longchampt, E., Cerf, C., Roux, A., & Brugière, O. (2021). A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. The European respiratory journal, 58(5), . https://doi.org/10.1183/13993003.04090-2020
Parquin, Francois, et al. "A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome." The European respiratory journal vol. 58,5 (2021). doi: https://doi.org/10.1183/13993003.04090-2020
Parquin F, Zuber B, Vallée A, Taupin JL, Cuquemelle E, Malard S, Neuville M, Devaquet J, Le Guen M, Fessler J, Beaumont L, Picard C, Hamid A, Colin de Verdière S, Grenet D, De Miranda S, Glorion M, Sage E, Pricopi C, De Wolf J, Brun AL, Longchampt E, Cerf C, Roux A, Brugière O. A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. Eur Respir J. 2021 Nov 18;58(5). doi: 10.1183/13993003.04090-2020. Print 2021 Nov. PMID: 34016620.
Copy Download .nbib Format: NLM
Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.

Human gene therapy

Bougnères P, Hacein-Bey-Abina S, Labik I, Adamsbaum C, Castaignède C, Bellesme C, Schmidt M.
PMID: 33789438
Hum Gene Ther. 2021 Oct;32(19):1260-1269. doi: 10.1089/hum.2021.053. Epub 2021 May 04.

In 2009, cerebral adrenoleukodystrophy (c-ALD) became the first brain disease to be treated with lentiviral (LV)-based hematopoietic stem cell gene therapy with the

Cite
Bougnères P, Hacein-Bey-Abina S, Labik I, et al. Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. Hum Gene Ther. 2021;32(19):1260-1269doi: 10.1089/hum.2021.053.
Bougnères, P., Hacein-Bey-Abina, S., Labik, I., Adamsbaum, C., Castaignède, C., Bellesme, C., & Schmidt, M. (2021). Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. Human gene therapy, 32(19), 1260-1269. https://doi.org/10.1089/hum.2021.053
Bougnères, Pierre, et al. "Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy." Human gene therapy vol. 32,19 (2021): 1260-1269. doi: https://doi.org/10.1089/hum.2021.053
Bougnères P, Hacein-Bey-Abina S, Labik I, Adamsbaum C, Castaignède C, Bellesme C, Schmidt M. Long-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. Hum Gene Ther. 2021 Oct;32(19):1260-1269. doi: 10.1089/hum.2021.053. Epub 2021 May 04. PMID: 33789438.
Copy Download .nbib Format: NLM
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.

Blood

Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini CB, Brugieres L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R.
PMID: 34657149
Blood. 2021 Oct 17; doi: 10.1182/blood.2020008136. Epub 2021 Oct 17.

Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance may develop. By applying...

Cite
Karaca Atabay E, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2021;doi: 10.1182/blood.2020008136.
Karaca Atabay, E., Mecca, C., Wang, Q., Ambrogio, C., Mota, I., Prokoph, N., Mura, G., Martinengo, C., Patrucco, E., Leonardi, G., Hossa, J., Pich, A., Mologni, L., Gambacorti-Passerini, C. B., Brugieres, L., Geoerger, B., Turner, S. D., Voena, C., Cheong, T. C., & Chiarle, R. (2021). Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, . https://doi.org/10.1182/blood.2020008136
Karaca Atabay, Elif, et al. "Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2020008136
Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini CB, Brugieres L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2021 Oct 17; doi: 10.1182/blood.2020008136. Epub 2021 Oct 17. PMID: 34657149.
Copy Download .nbib Format: NLM
Showing 61 to 68 of 68 entries